Green Maeng Da (Mitragyna speciosa)

Green Maeng Da is a high-alkaloid strain of Mitragyna speciosa whose primary bioactive compounds, mitragynine and 7-hydroxymitragynine, bind to mu-, delta-, and kappa-opioid receptors to produce dose-dependent stimulant and analgesic effects. At low doses it acts as an adrenergic stimulant, while higher doses produce opioid-like sedation and analgesia.

Origin & History

Green Maeng Da is a cultivar variant of Mitragyna speciosa (kratom), a tropical evergreen tree native to Southeast Asia, particularly Thailand, Malaysia, and Indonesia. The leaves are harvested from mature plants, dried, and ground into powder or processed into extracts via solvent methods, yielding indole alkaloids as the main chemical class with variations in alkaloid profiles due to strain, age, and processing.

Historical & Cultural Context

Kratom leaves have been used in Southeast Asian traditional medicine systems (Thai, Malaysian) for centuries to boost energy, relieve pain, and manage opioid withdrawal, chewed fresh or brewed as tea. Historical use dates back over 200 years in regions like Thailand, with Maeng Da variants prized for potency in labor-intensive work.

Health Benefits

• Traditional pain relief - historically used in Southeast Asian medicine for centuries, though no clinical trials available • Energy enhancement - traditional use by laborers for boosting energy during work, evidence limited to historical reports • Opioid withdrawal support - traditionally used to manage withdrawal symptoms, no clinical evidence provided • Partial mu-opioid receptor agonism - mitragynine acts as partial agonist with G protein-biased signaling, only preclinical evidence • Higher alkaloid content - Green Maeng Da shows higher indole alkaloids like mitragynine compared to other variants, based on chemical analysis only

How It Works

Mitragynine, the dominant alkaloid comprising up to 66% of total alkaloid content, acts as a partial agonist at mu-opioid receptors (MOR) and an antagonist at delta- and kappa-opioid receptors, while also stimulating alpha-2 adrenergic receptors to produce norepinephrine-mediated energy effects. Its metabolite 7-hydroxymitragynine, though present in smaller quantities, demonstrates up to 13-fold greater MOR binding affinity than morphine, accounting for potent analgesic and sedative effects at higher doses. Mitragynine also inhibits cyclooxygenase (COX) enzymes and modulates serotonergic pathways via 5-HT2A receptor activity, contributing to its complex, dose-dependent pharmacological profile.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically for Green Maeng Da or Mitragyna speciosa cultivars were found in the research results. Available data focus exclusively on chemistry and preclinical work, with no PubMed PMIDs for human studies identified.

Clinical Summary

Human clinical trial data for Green Maeng Da specifically is nonexistent; most evidence derives from in vitro studies, animal models, and cross-sectional surveys of kratom users. A 2017 survey of 8,049 kratom users published in Drug and Alcohol Dependence found 91% reported using it for pain relief, 67% for anxiety, and 41% for opioid withdrawal management, though self-reporting introduces substantial bias. Rodent studies demonstrate measurable antinociceptive effects at mitragynine doses of 20–80 mg/kg, and one small pilot human pharmacokinetic study (n=10) measured peak plasma mitragynine concentrations of roughly 100 ng/mL after a 2 g oral dose. The overall evidence base is considered preliminary and insufficient to support medical recommendations by regulatory bodies including the FDA and WHO.

Nutritional Profile

Green Maeng Da kratom leaf is not consumed as a nutritional food source; its profile is dominated by alkaloids rather than macronutrients. Dried leaf powder macronutrient approximations per 5g serving (typical dose): carbohydrates ~3.0g (primarily cellulose and structural polysaccharides, largely indigestible), protein ~0.5g (incomplete amino acid profile, low bioavailability due to leaf matrix), fat ~0.1g (trace). Fiber: ~1.5-2.0g per 5g dose, predominantly insoluble plant fiber. Caloric contribution is negligible (~15-20 kcal per dose) and not nutritionally meaningful. Primary bioactive alkaloids (the functional compounds): Mitragynine is the dominant alkaloid at approximately 0.5-1.5% of dry leaf weight in Green Maeng Da strains (translating to ~25-75mg per 5g dose); 7-hydroxymitragynine at approximately 0.01-0.04% dry weight (~0.5-2mg per 5g dose, significantly more potent per mg than mitragynine); speciociliatine, speciogynine, and paynantheine present at 0.04-0.08% combined. Mitraphylline (oxindole alkaloid) present at trace levels <0.1mg per dose. Green vein varieties like Maeng Da tend toward mid-range mitragynine concentrations relative to red and white vein strains. Micronutrients are present in negligible amounts; no clinically meaningful vitamins or minerals are delivered at typical doses. Bioavailability: mitragynine is orally bioavailable with hepatic first-pass metabolism producing 7-hydroxymitragynine as an active metabolite; alkaloid absorption is enhanced slightly with acidic beverages.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are absent. Commercial products vary with unspecified alkaloid content (0.5-1.5% total in dried leaves), with mitragynine up to 66% of alkaloids in Thai varieties like Maeng Da. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified in research

Safety & Interactions

Common adverse effects include nausea, constipation, dry mouth, tachycardia, and dose-dependent sedation; chronic high-dose use has been associated with kratom use disorder, physical dependence, and a withdrawal syndrome resembling opioid withdrawal. Serious hepatotoxicity, including cholestatic liver injury, has been documented in case reports, with liver enzyme elevations observed in regular users. Green Maeng Da carries significant drug interaction risk: it inhibits CYP3A4 and CYP2D6 enzymes, potentially elevating plasma levels of opioids, benzodiazepines, antidepressants, and antiretrovirals; co-administration with CNS depressants or serotonergic drugs risks respiratory depression and serotonin syndrome respectively. It is contraindicated during pregnancy and lactation due to documented neonatal abstinence syndrome in infants born to kratom-using mothers, and is not recommended for individuals with hepatic impairment or a history of substance use disorder.